Kaletra Oral Solution and Lorbrena

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Ritonavir may significantly increase the blood levels of lorlatinib. This may increase the risk of serious side effects such as seizures, hallucinations, cognitive problems (e.G., confusion, forgetfulness, difficulty concentrating), mood disorders (e.G., depression), sleep impairment, increases in cholesterol and triglycerides, slow or abnormal heartbeats, and inflammation of the lungs. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should contact your doctor if you experience dizziness, lightheadedness, abnormal heartbeats, or any new or worsening lung problems such as difficulty breathing, shortness of breath, cough, or fever. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of lorlatinib, which has been found to be metabolized primarily by CYP450 3A4 and UGT1A4 in vitro. According to the product labeling, administration of a single 100 mg oral dose of lorlatinib with itraconazole, a potent CYP450 3A4 inhibitor, increased lorlatinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 24% and 42%, respectively. Increased exposure to lorlatinib may increase the risk of central nervous system adverse effects (e.g., seizures, hallucinations, changes in cognitive function, mood disorders, mental status changes, sleep impairment), hyperlipidemia (hypercholesterolemia and hypertriglyceridemia), PR interval prolongation and atrioventricular (AV) block, and interstitial lung disease/pneumonitis.

MANAGEMENT: Concomitant use of lorlatinib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the initial dosage of lorlatinib should be reduced from 100 mg orally once daily to 75 mg orally once daily. In patients who have had a dosage reduction to 75 mg orally once daily due to adverse reactions, the lorlatinib dosage should be further reduced to 50 mg orally once daily upon initiation of a potent CYP450 3A4 inhibitor. After 3 plasma half-lives following discontinuation of the potent CYP450 3A4 inhibitor, the lorlatinib dosage may be increased to that used prior to initiation of the inhibitor.

Kaletra Oral Solution

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: Kaletra

What is Kaletra Oral Solution?

Lorbrena

Generic Name: lorlatinib

Brand name: Lorbrena

Synonyms: n.a.

What is Lorbrena?